[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587040":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":12,"collaborators":10,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":21,"acronym":10,"eligibilityCriteria":22,"healthyVolunteers":18,"sex":23,"minAge":24,"maxAge":25,"enrollmentInfo":26,"targetDuration":10,"studyType":29,"phases":10,"briefSummary":30,"conditions":31,"keywords":33,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adults with suspected\u002Fconfirmed metabolic syndrome",null,"Adults (18-65 years) with suspected\u002Fconfirmed metabolic syndrome (IDF criteria) attending a metabolic clinic in Egypt over 12 months. Exclusions include other liver diseases, high alcohol intake, pregnancy, or advanced cirrhosis.",{"type":13,"investigatorFullName":14,"investigatorTitle":15,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Amira William Ayad Makar","resident at the tropical medicine and gastroenterology in Assuit university.","100587040","glucose-disposal-rate-as-a-metric-for-detection-of-metabolic-associated-fatty-liver-100587040",false,"NCT06923215","Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver","The Role of Estimated Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver Disease and Its Severity in Patients With Metabolic Syndrome.","Inclusion Criteria:\n\n* Age 18-65 years.\n* Suspected\u002Fconfirmed MS per IDF criteria:\n* Central obesity (waist circumference ≥94 cm \\[men\\]\u002F≥80 cm \\[women\\]) plus ≥2 of: Triglycerides ≥150 mg\u002FdL.\n\nHDL \\\u003C40 mg\u002FdL (men)\u002F\\\u003C50 mg\u002FdL (women). Blood pressure ≥130\u002F85 mmHg or antihypertensive treatment. Fasting glucose ≥100 mg\u002FdL or diabetes diagnosis.\n\nExclusion Criteria:\n\n* Other liver diseases (viral\u002Fautoimmune hepatitis).\n\nAlcohol intake \\>20 g\u002Fday (men) or \\>10 g\u002Fday (women).\n\nPregnancy, malignancy, advanced cirrhosis.\n\nMedications affecting metabolism (e.g., steroids)","ALL","18 Years","65 Years",{"count":27,"type":28},30,"ESTIMATED","OBSERVATIONAL","A 12-month prospective observational cohort study assessing eGDR's utility in diagnosing MAFLD (via FibroScan® CAP ≥248 dB\u002Fm) and correlating it with steatosis\u002Ffibrosis severity. Secondary aims compare eGDR to FLI\u002FFIB-4 scores and identify optimal diagnostic cut-offs",[32],"MAFLD",[32,34,35],"eGDR","Fibroscan","NOT_YET_RECRUITING","2025-04-04",{"date":39,"type":40},"2025-04-11","ACTUAL",{"date":42,"type":28},"2025-07-30",{"date":44,"type":28},"2026-12-30",{"name":5,"class":6}]